HEBERSaVax (CIGB-247) / Center for Genetic Engineering and Biotechnology, Heber Biotec - LARVOL DELTA

HEBERSaVax immunotherapy combined with first-line chemotherapy in advanced ovarian cancer: Phase II CENTAURO-4 trial results. (PubMed, Int J Cancer) - "We present results from the multicenter, open-label CENTAURO 4 phase 2 trial evaluating two formulations of HEBERSaVax combined with carboplatin/paclitaxel in advanced epithelial ovarian cancer patients (unresectable or suboptimal debulked). No statistically significant differences emerged between the VSSP and aluminum phosphate adjuvant formulations for either safety or efficacy endpoints. These clinical outcomes and the vaccine's favorable toxicity profile position HEBERSaVax as a promising immunotherapeutic strategy for improving epithelial ovarian cancer management."

Journal • P2 data • Epithelial Ovarian Cancer • Oncology • Ovarian Cancer • Solid Tumor

VEGF-Specific cellular response associated to a cancer therapeutics vaccine administration: From bench to bedside (CIMT 2024) - "So far HEBERSaVax is the only active immunotherapeutic intervention using VEGF as a target that has managed to induce VEGF-specific cellular response. Of higher importance, such response was associated in terms of its presence and intensity with the increment in overall survival of the patients within the clinical studies."

IO biomarker • Oncology • IFNG • KDR • VEGFA

VEGF-Specific cellular response associated to a cancer therapeutics vaccine administration: From bench to bedside. (CIMT 2024) - "So far HEBERSaVax is the only active immunotherapeutic intervention using VEGF as a target that has managed to induce VEGF-specific cellular response. Of higher importance, such response was associated in terms of its presence and intensity with the increment in overall survival of the patients within the clinical studies."

IO biomarker • Oncology • IFNG • KDR • VEGFA

Preclinical and clinical significance of VEGF deprivation in ovarian cancer through a specific active immunotherapy (ESMO 2023) - "Processing of phase II clinical trial (RPCEC00000246) immune variables evaluations is ongoing (n=38, final data: ESMO). Conclusions Our findings indicate that HEBERSavax's impact on preclinical ID8 settings might be translatable to a positive outcome in advanced OvCan patients."

IO biomarker • Preclinical • Oncology • Ovarian Cancer • Solid Tumor • IFNG

Modulating tumor microenvironment using a VEGF active immunotherapeutic approach in gastrointestinal tumors: Beyond angiogenesis modulation (ESMO 2023) - "Conclusions CIGB-247 antigen-based vaccine increased tumor-infiltrating lymphocytes and reversed the immunosuppressive effect of the tumor microenvironment in the CT26 mouse model. Such results were corroborated in a GIC patient cohort indicating that the strategy might be a successful treatment option for such patients by modifying systemic and tumor microenvironment beyond angiogenesis modulation."

Biomarker • Tumor microenvironment • Colon Cancer • Colorectal Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor • CD8 • CXCL1 • IFNG • KDR